Affordable Access

Teniposide is not effective in chronic lymphocytic leukemia.

Authors
Type
Published Article
Journal
Blut
Publication Date
Volume
52
Issue
1
Pages
59–61
Identifiers
PMID: 3632912
Source
Medline
License
Unknown

Abstract

Teniposide has been evaluated in a phase II clinical trial in chronic lymphocytic leukemia (CLL). Among 16 consecutive patients with CLL entered in the study and treated with Teniposide, 100 mg/m2 weekly, no objective response was observed. Toxicity was generally mild and mainly hematologic. Teniposide at this dosage and schedule is an inactive drug in CLL.

Statistics

Seen <100 times